Melphalan

Generic Name: Melphalan

Brand Names: Alkeran, Evomela, Phelinun, Pepaxti

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈Cl_₂N_₂O_₂

CAS Number: 148-82-3

Unique Ingredient Identifier: Q41OR9510P

Background: Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication: Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions: Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-08-05

Last Posted Date: 2013-04-17

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 3

Registration Number: NCT00003957

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver

Phase 2

Completed

Conditions: Colorectal Cancer
Metastatic Cancer

First Posted Date: 2004-08-05

Last Posted Date: 2012-05-14

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 8

Registration Number: NCT00089401

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2004-08-05

Last Posted Date: 2013-01-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00089167

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Graft Versus Host Disease
Leukemia
Lymphoma
Myelodysplastic Syndromes
Neuroblastoma

First Posted Date: 2004-08-04

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 3

Registration Number: NCT00003661

Locations: 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸
Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States

and more 14 locations

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Phase 2

Completed

Conditions: Graft Versus Host Disease
Leukemia
Myelodysplastic Syndromes
Thymic Carcinoma

First Posted Date: 2004-08-04

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 90

Registration Number: NCT00003662

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
University of Florida Health Science Center, Gainesville, Florida, United States

and more 12 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

First Posted Date: 2004-08-03

Last Posted Date: 2019-10-17

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 32

Registration Number: NCT00003413

Locations: 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: recombinant interferon alfa
Drug: dexamethasone
Drug: melphalan
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-08-03

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 9

Registration Number: NCT00003416

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States

and more 81 locations

High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2004-07-29

Last Posted Date: 2011-05-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 50

Registration Number: NCT00002630

Locations: 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-07-22

Last Posted Date: 2012-02-22

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 61

Registration Number: NCT00003392

Locations: 🇺🇸
Bone Marrow Stem Cell Transplant Institute of Florida, Fort Lauderdale, Florida, United States
🇺🇸
Lutheran General Cancer Care Center, Park Ridge, Illinois, United States
🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

and more 11 locations

Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2004-07-19

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00004158

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Sylvester Cancer Center, University of Miami, Miami, Florida, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy